跳转至内容
Merck
CN

MAB4381C3

Anti-TRA-1-81 Antibody, clone TRA-1-81, Cy3 conjugate

clone TRA-1-81, from mouse, CY3 conjugate

别名:

Podocalyxin, GCTM-2 antigen, Gp200, Podocalyxin-like protein 1

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
CY3 conjugate
Clone:
TRA-1-81, monoclonal
Application:
ICC
Citations:
5
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

biological source

mouse

conjugate

CY3 conjugate

antibody form

saturated ammonium sulfate (SAS) precipitated

antibody product type

primary antibodies

clone

TRA-1-81, monoclonal

species reactivity

human

technique(s)

immunocytochemistry: suitable

isotype

IgM

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Quality Level

Gene Information

human ... PODXL(5420)

General description

420/250 kDa calculated
TRA-1-81 is expressed upon the surface of human teratocarcinoma stem cells (EC), human embryonic germ cells (EG) and human embryonic stem cells (ES). Both TRA-1-81 and TRA-1-60 recognize antigens that are associated with a pericellular matrix proteoglycan. TRA-1-60 reacts with a sialidase-sensitive epitope while TRA-1-81 reacts with an unknown epitope of the same molecule. TRA-1-81 is commonly used as marker of undifferentiated pluripotent human stem cells and is downregulated upon differentiation. TRA-1-81 has recently been identified as podocalyxin.

Immunogen

Human embryonal carcinoma cell line 2102Ep

Application

Evaluated by Immunocytochemistry in mouse embryonic stem cells (SCR012). Immunocytochemsitry Analysis: A 1:100 dilution of this antibody did not detect TRA-1-81 in mouse embryonic stem cells (SCR012).
Research Category
Stem Cell Research
Research Sub Category
Pluripotent & Early Differentiation
This Anti-TRA-1-81 Antibody, clone TRA-1-81, Cy3 conjugate is validated for use in ICC for the detection of TRA-1-81.

Biochem/physiol Actions

This antibody recognizes human TRA-1-81.

Physical form

Purified mouse monoclonal IgM conjugated to Cy3 in PBS with 0.1% sodium azide and 15mg/ml BSA.

Preparation Note

Maintain refrigerated at 2-8ºC protected from light in undiluted aliquots for up to 6 months from date of receipt.

Analysis Note

Control
H9 human embryonic stem cells
Evaluated by Immunocytochemistry in H9 human embryonic stem cells.
Immunocytochemsitry Analysis: A 1:100 dilution of this antibody detected TRA-1-81 in H9 human embryonic stem cells.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

存储类别

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Xinyu Liu et al.
Cell division, 15(1), 12-12 (2020-12-10)
Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) has opened new therapeutic possibilities. However, karyotypic abnormalities detected in iPSCs compromised their utility, especially chromosomal aberrations found at early passages raised serious safety concerns. The mechanism underlying the chromosomal abnormality
Daniel Rodrigo Marinowic et al.
Molecular medicine reports, 15(4), 2049-2056 (2017-03-06)
Focal cortical dysplasia (FCD) is caused by numerous alterations, which can be divided into abnormalities of the cortical architecture and cytological variations; however, the exact etiology of FCD remains unknown. The generation of induced pluripotent stem cells (iPSCs) from the
Christian A Di Buduo et al.
eLife, 10 (2021-06-02)
Thrombocytopenic disorders have been treated with the Thrombopoietin-receptor agonist Eltrombopag. Patients with the same apparent form of thrombocytopenia may respond differently to the treatment. We describe a miniaturized bone marrow tissue model that provides a screening bioreactor for personalized, pre-treatment

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持